On the company’s first-quarter earnings call, first reported by Reuters, CFO Jochen Schmitz confirmed the strategy shift. He said the “use of Corindus robots for cardiology operations did not fulfill our expectations.” Schmitz reportedly added that the timeline for robots for neurological operations to reach the market constitutes “several years.”
In 2019, Siemens Healthineers bought out Corindus for $1.1 billion. Corindus develops the CorPath robot-assisted device for coronary and peripheral vascular procedures.
The business arm aims to provide innovative, image-guided robotic solutions. Its CorPath GRX system supports endovascular procedures.
It officially rebranded to “Siemens Healthineers Endovascular Robot…